Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients.

The U.S. Food and Drug Administration (FDA) has approved Celltrion’s AVTOZMA (CT-P47, tocilizumab-anoh) in both an ...

Celltrion, a major South Korean biopharmaceutical firm, on Friday said its new biosimilar for an autoimmune disease treatment has received approval from the US Food and Drug Administration (FDA). The ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both ...

The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a biosimilar to Actemra ® (tocilizumab), in both intravenous (IV) and subcutaneous (SC) formulations.

Celltrion's biosimilar Avtozma, used to treat inflammatory diseases, was approved for the U.S. market by the Food and Drug Administration.

South Korean biopharma contract manufacturer Celltrion is considering acquiring US manufacturing sites to mitigate President ...

Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) announced today that it has received approval for a partial amendment to the ...

Rise in prevalence of ulcerative colitis and Crohn's disease, growing awareness of the disease across the world, drives the growth of the market David Correa Allied Market Research + 1 800-792-5285 ...

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.

JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...